Talazoparib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TALAZOPARIB |
|---|---|
| Type | Drug |
| Aliases | TalzennaТалазопариб |
| Status | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | PARP inhibitor (PARP-trapper) |
|---|---|
| Mechanism | PARP1/2 inhibitor with greater PARP-trapping activity than olaparib — physically traps PARP on DNA, enhancing cytotoxicity in HRR-deficient cells. TALAPRO-2 trial established mCRPC indication combined with enzalutamide. |
| Typical dosing | Combined with enzalutamide (TALAPRO-2): talazoparib 0.5 mg PO daily + enzalutamide 160 mg PO daily. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Combination with enzalutamide for mCRPC 1L improves rPFS vs enzalutamide alone (TALAPRO-2). UA-access major barrier.
Used By
Regimens
REG-TALAZOPARIB-MONO-BREAST- Talazoparib monotherapy (gBRCA-mutant HER2- locally advanced or metastatic breast)